Indication of «Liziniy» (2.5% solution for injections, a product of «Pharmatron» RPC) in the dose of 50 mg/kg simultaneously with development of acute myocardial infarction in the experiment results in normalization of the energy metabolism of the heart due to intensification of aerobic reactions and compensatory activation of malate-aspartate shunt, decrease of anaerobic glycolysis and improvement of mitochondria functions and thereby forms resistance of the myocardium to hypoxia due to change of energy tracts expecting mobilization of the protons supply mechanism for oxidative phosphorylation and the saving use of deficient oxygen. The therapeutical efficiency of «Liziniy» exceeds significantly the efficiency of reference medicine – mildronate.
Key words: metabolitotropic cardioprotectors, “Liziniy”, myocardial infarction, energy metabolism
